ArticleIn silico pharmacology2025
Targeting SARS-CoV-2 variants with Bromelain: an in-silico study of Spike-ACE2 inhibition using docking, molecular dynamic simulation, and MM-PBSA.
Article in In silico pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2, responsible for COVID-19, continue to pose a significant global health challenge due to its high transmissibility and ability to evolve through mutations. The SARS-CoV-2 spike protein mediates viral entry by binding to the ACE2 receptor, making it a crucial target for therapeutics, with efforts focused on blocking this interaction to develop effective treatments against the virus and its evolving variants. Our study investigates the potential of Bromelain, a plant-derived protease, as a competitive inhibitor of ACE2 binding. We analysed the receptor-binding domain (RBD) of spike proteins from variants prevalent in the Indian subregion, including Wuhan, Delta, Omicron, JN.1.1, and JN.1.4. Sequence analysis revealed several mutations in emerging variants, with JN.1.1 and JN.1.4 exhibiting the highest levels of variation. Docking studies showed that Bromelain occupied ACE2 binding sites within the RBD at varying levels 57.89% for Wuhan, 42.1% for Delta, 47.36% for Omicron, 52.6% for JN.1.1, and 68.42% for JN.1.4, suggesting a competitive inhibition mechanism. Molecular dynamics simulations confirmed stable interactions across the variants. MM/PBSA calculations further validated Bromelain's interactions, supported by Principal Component analysis and Free Energy Landscape studies, with JN.1.4 demonstrating the strongest binding affinity. These findings align with prior studies demonstrating Bromelain's antiviral properties, including its ability to degrade viral proteins. Our findings highlight Bromelain as a promising antiviral candidate against emerging SARS-CoV-2 variants, particularly JN.1.1 and JN.1.4. Further in-vitro and in-vivo studies are suggested to explore Bromelain's therapeutic efficacy. Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-025-00446-x.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.